314 In the index

MK-0773 MK-0773

An experimental muscle-building compound from a major drug company, tested in a human trial for age-related muscle loss in women. The trial didn't show a good enough balance of benefits versus side effects, including unwanted voice and hair changes, so development was stopped.

Also known as MK0773, 5730VNW22X, RefChem:1050466, MK 0773, PF 05314882, C27H34FN5O2, orb1706975, EX-A10911, T16090

Effects Build muscle

Routes Oral

Legal status Research chemical

WADA Banned at all times

3D Molecular Structure of C₂₇H₃₄FN₅O₂

Drag to rotate · scroll to zoom

Chemistry

Formula: C27H34FN5O2
Molar mass: 479.6
CAS: 606101-58-0
PubChem CID: 11950726
IUPAC name: (1S,3aS,3bS,5aR,9aS,9bS,11aS)-8-fluoro-N-(1H-imidazo[4,5-b]pyridin-2-ylmethyl)-6,9a,11a-trimethyl-7-oxo-2,3,3a,3b,4,5,5a,9b,10,11-decahydro-1H-indeno[5,4-f]quinoline-1-carboxamide
InChIKey: GBEUKTWTUSPHEE-JWJWXJQQSA-N

Reported dosing

Clinical data

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose Not established (development discontinued)

Reported range Phase II trial doses: 50-200 mg/day (studied in sarcopenic women)

Route Oral

Frequency Once daily (trial protocol)

Duration Trial duration of 6 months

A SARM candidate (Merck) that failed to show sufficient functional benefit in its Phase II trial for sarcopenia; development was discontinued, and it was never approved.

Where this comes from Published Phase II clinical trial data (Merck)

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.